Goldman Sachs Initiates Coverage on Horizon Pharma PLC(NASDAQ:HZNP). The shares have been rated Buy. The rating by Goldman Sachs was issued on Jun 6, 2016.
In a different note, On Apr 25, 2016, Citigroup said it Maintains its rating on Horizon Pharma PLC. In the research note, the firm Lowers the price-target to $21.00 per share. The shares have been rated ‘Neutral’ by the firm.
Horizon Pharma PLC (HZNP) shares turned negative on Fridays trading session with the shares closing down -0.65 points or -3.51% at a volume of 25,87,579. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $18.265. The peak price level was also seen at $18.265 while the days lowest was $17.75. Finally the shares closed at $17.88. The 52-week high of the shares is $39.49 while the 52-week low is $12.86. According to the latest information available, the market cap of the company is $2,867 M.
Horizon Pharma PLC(HZNP) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $204.69M. Analysts had an estimated revenue of $198.69M. Earnings per share were $0.34. Analysts had estimated an EPS of $0.31.
Several Insider Transactions has been reported to the SEC. On Dec 10, 2015, Jeffrey W Sherman (EVP and Chief Medical Officer) sold 4,456 shares at $20.00 per share price.Also, On Aug 21, 2015, Thomas Watkins (director) purchased 10,000 shares at $31.32 per share price.On Mar 17, 2015, Jeff Himawan (director) sold 554,564 shares at $22.47 per share price, according to the Form-4 filing with the securities and exchange commission.
Horizon Pharma plc formerly Vidara Therapeutics International Public Limited Company is a specialty biopharmaceutical company focused on identifying developing acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis inflammation and orphan diseases. The Company’s the United States marketed products are ACTIMMUNE (interferon gamma-1b) DUEXIS (ibuprofen/famotidine) PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA has the United States rights to VIMOVO has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.